Source: HIV Medicine. Unidade: FMRP
Subjects: PEDIATRIA, FARMACOCINÉTICA, ANTIVIRAIS, INFECÇÕES POR HIV
ABNT
TUDOR-WILLIAMS, G. et al. Etravirine in treatment-experienced, HIV-1-infected chidren and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study. HIV Medicine, v. 15, n. 9, p. 513-524, 2014Tradução . . Disponível em: https://doi.org/10.1111/hiv.12141. Acesso em: 05 jun. 2024.APA
Tudor-Williams, G., Cahn, P., Chokephaibulkit, K., Fourie, J., Karatzios, C., Dincq, S., et al. (2014). Etravirine in treatment-experienced, HIV-1-infected chidren and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study. HIV Medicine, 15( 9), 513-524. doi:10.1111/hiv.12141NLM
Tudor-Williams G, Cahn P, Chokephaibulkit K, Fourie J, Karatzios C, Dincq S, Opsomer M, Nakuda TN, Nijs S, Tambuyzer L, Tomaka FL, Mussi-Pinhata MM. Etravirine in treatment-experienced, HIV-1-infected chidren and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study [Internet]. HIV Medicine. 2014 ; 15( 9): 513-524.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1111/hiv.12141Vancouver
Tudor-Williams G, Cahn P, Chokephaibulkit K, Fourie J, Karatzios C, Dincq S, Opsomer M, Nakuda TN, Nijs S, Tambuyzer L, Tomaka FL, Mussi-Pinhata MM. Etravirine in treatment-experienced, HIV-1-infected chidren and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study [Internet]. HIV Medicine. 2014 ; 15( 9): 513-524.[citado 2024 jun. 05 ] Available from: https://doi.org/10.1111/hiv.12141